Best Options Strategy for RCKT
Looking for the best options strategy for Rocket Pharmaceuticals, Inc. (RCKT)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live RCKT option chain right now, and a simple map from your view on RCKT to the strategy that fits it. Model any of them in the calculator before you trade.
About Rocket Pharmaceuticals, Inc.
# About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals is a biotechnology company in the advanced stages of development focused on gene therapies for rare genetic disorders. The company works with two main technological platforms: in vivo adeno-associated viral vectors and ex vivo lentiviral vectors. On the viral side, it is developing treatments for several inherited cardiac conditions—Danon disease (currently in Phase 2 trials), plakophilin-2 arrhythmogenic cardiomyopathy (Phase 1), and BAG3 dilated cardiomyopathy (preclinical)—all of which cause progressive heart damage and life-threatening complications. The lentiviral program targets blood and immune disorders including leukocyte adhesion deficiency, Fanconi anemia, and pyruvate kinase deficiency, where gene correction aims to restore defective cell production or immune function.
Revenue generation remains limited at this stage, as most candidates are still in clinical trials and none have reached commercialization. The company operates primarily in the United States and has established licensing partnerships with several research institutions and universities, including UCL Business and the University of California,…
Today's top-scoring strategy for RCKT
Our engine ranks defined-risk strategies on the live RCKT chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $2.5 | $0.07 |
| Sell | 1× | PUT | $2.5 | $0.07 |
| Sell | 1× | CALL | $2.5 | $1.70 |
| Buy | 1× | CALL | $7.5 | $0.05 |
Simulazione
Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.
Analisi della strategia
Greche vs prezzo
Prezzo × volatilità (oggi)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $5 | −$39 | −$35 | −$30 | −$25 | −$19 |
| $4 | −$23 | −$20 | −$17 | −$13 | −$8 |
| $4 | −$6 | −$5 | −$3 | −$0 | $3 |
| $4 | $11 | $10 | $11 | $12 | $15 |
| $4 | $27 | $26 | $25 | $25 | $26 |
| $4 | $44 | $41 | $39 | $38 | $38 |
| $3 | $60 | $56 | $53 | $51 | $49 |
| $3 | $75 | $71 | $66 | $63 | $61 |
| $3 | $90 | $85 | $80 | $76 | $73 |
| $3 | $104 | $98 | $92 | $88 | $84 |
| $3 | $117 | $111 | $105 | $99 | $95 |
Live scan from 2026-07-15 · quotes delayed ~15 minutes
Backtest storico: come si sarebbe comportata una Iron Butterfly su RCKT
Abbiamo simulato in modo approssimativo una Iron Butterfly su RCKT che avresti aperto ripetutamente nell'ultimo anno (92 ingressi storici, ciascuno mantenuto fino alla scadenza), con i premi d'ingresso modellati tramite Black-Scholes. Ecco come sarebbe andata sulla reale storia dei prezzi di RCKT — un backtest didattico, non una previsione dei rendimenti futuri.
In via approssimativa: i premi d'ingresso sono modellati con Black-Scholes sulla base della volatilità realizzata trailing, mantenuti fino alla scadenza e regolati contro il reale prezzo di chiusura storico. Fill reali, volatilità implicita e slippage differiscono — consideralo come contesto indicativo, non come rendimento esatto.
Implied volatility
RCKT is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 147% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on RCKT currently price in about 147% implied volatility, versus roughly 67% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$1,7 (±46%) in RCKT by 2026-08-21 — a range of roughly $1,96 to $5,37. Strikes inside that band hold most of the premium and see most of the action.
In evidenza dalla option chain di RCKT: open interest, volume e skew
La option chain live di RCKT mostra un rapporto put/call sull'open interest di 0.02 (bullish-leaning (more calls)), con una volatilità implicita at-the-money intorno al 184.8%. L'open interest si concentra sulla call a 5 — un classico "muro" di resistenza — e sulla put a 2.5, un "muro" di supporto: esattamente gli strike a cui gli scrittori di opzioni sono più esposti verso la scadenza.
Istantanea di open interest, volume e volatilità implicita per la scadenza scansionata più vicina — contesto, non un segnale di trading.
Insider trading su RCKT (SEC Form 4)
Operazioni degli insider sul mercato aperto relative a RCKT negli ultimi sei mesi circa, tratte dalle comunicazioni SEC Form 4. Gli acquisti sul mercato aperto sono il segnale più raro e più forte — le vendite di routine effettuate nell'ambito di piani prestabiliti sono frequenti, quindi leggi un dato di vendita netta tenendolo presente.
| Insider | Azione | Azioni | Valore | Data |
|---|---|---|---|---|
| Shah Gaurav | Vendita | 55.684 | $172K | 2026-05-21 |
| Shah Gaurav | Vendita | 2409 | $7K | 2026-05-19 |
| Wilson Martin | Vendita | 662 | $2K | 2026-05-19 |
| Militello John | Vendita | 384 | $1K | 2026-05-19 |
| Shah Gaurav | Vendita | 2728 | $10K | 2026-05-13 |
| Wilson Martin | Vendita | 3361 | $12K | 2026-05-13 |
Fonte: comunicazioni SEC Form 4 tramite Finnhub. Solo acquisti (P) e vendite (S) sul mercato aperto — assegnazioni, esercizi di opzioni, donazioni e ritenute fiscali sono esclusi. Contesto informativo, non consulenza sugli investimenti.
Earnings & IV crush
RCKT's next earnings report is due around 6 agosto 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
With earnings roughly 15 days out, RCKT's 147% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.
Key figures
- Market cap
- $360M
- Beta (vs market)
- 0.45
- 52-week range
- $2.53–$5.45 (39% up the range)
- Short interest
- 20.4% of float · 5.8 days to cover
With 20.4% of RCKT's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for RCKT
If your view on RCKT differs, these also scored well in the latest scan:
How to choose an options strategy for RCKT
Start with your outlook on RCKT, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while RCKT stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open RCKT in the free calculator →
Domande frequenti
What is the best options strategy for RCKT?
It depends on your outlook. Bullish traders often use a long call or bull call spread on RCKT; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are RCKT options liquid enough to trade?
Rocket Pharmaceuticals, Inc. (RCKT) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade RCKT options?
Buying a single RCKT call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade RCKT or any security. Do your own research.
Cosa fa Rocket Pharmaceuticals, Inc.?
Rocket Pharmaceuticals, Inc. (RCKT) opera nel settore Biotechnology. La sezione "Informazioni su Rocket Pharmaceuticals, Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.
Rocket Pharmaceuticals, Inc. paga dividendi?
Qui non mostriamo un rendimento da dividendo confermato per Rocket Pharmaceuticals, Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.
Quando Rocket Pharmaceuticals, Inc. pubblica gli utili?
I prossimi utili di Rocket Pharmaceuticals, Inc. sono attesi intorno al 6 agosto 2026. La volatilità implicita di solito sale in avvicinamento alla pubblicazione e crolla bruscamente dopo (IV crush) — un aspetto importante per qualsiasi posizione in opzioni che mantieni oltre quella data.
Tickers related to RCKT
Comparing RCKT with similar names can help you choose the best options strategy:
Informazioni sull’azienda
- Sede
- 9 Cedarbrook Drive, Cranbury, NJ, 08512, United States
- Settore
- Biotechnology
- Dipendenti
- 202
- CEO
- Dr. Gaurav D. Shah M.D.
- Telefono
- 609 659 8001
- Sito web
- www.rocketpharma.com
Best Options Strategy by Ticker →
Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.